Implications of varied patterns of cervical cancer screening for introduction of human papillomavirus vaccines in Europe

Journal of the Turkish German Gynecology Association

Volumn 10, Issue 2, 2009, Pages 61-67

  Schneider, Achim ^a   Gleizes, Olivier ^b   Nieminen, Pekka ^c   Erdemoǧlu, Evrim ^a   Boselli, Fausto ^d   Jenkins, David ^e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Smart Pharma Consulting   (France)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Cervical cancer; European countries; Screening programmes; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER REGISTRY; CANCER SCREENING; FEMALE; HEALTH PROGRAM; HUMAN; MASS SCREENING; PAPANICOLAOU TEST; PRACTICE GUIDELINE; SECONDARY PREVENTION; UTERINE CERVIX CANCER;

EID: 68749095291     PISSN: 13090399     EISSN: 13090380     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Anttila A, Ronco G, Clifford G, Bray F, Hakama M, Arbyn M et al. Cervical cancer screening programmes and policies in 18 European countries. Br J Cancer. 2004; 91: 935-41.
2. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002; 347: 1645-51.
3. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A et al. Efficacy of a bivalent L1 virus-like particle vaccine in preventio of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757-65.
4. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006; 367: 1247-55.
5. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR et al. Prophylactic quadrivalent human papillomavirus (types 6,11,16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005; 6: 271-8.
6. Goldie SJ, Kim JJ, Myers E. Cost-effectiveness of cervical cancer screening. Vaccine. 2006; 24: S164-S170.
7. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007; 356: 1915-27.
8. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928-43.
9. Hakama M, Coleman MP, Alexe DM, Auvinen A. Cancer screening: Evidence and practice in Europe 2008. Eur J Cancer. 2008; 44: 1404-13
10. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004; 96: 604-15.
11. Garnett GP, Kim JJ, French K, Goldie SJ. Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine. 2006; 24: S178-S186.
12. Muscat M, Glismann S, Bang H. Measles in Europe in 2001-2002. Euro Surveill. 2003; 8: 123-9.